Discover PLUVICTO

Identifying Patients

AFTER YOUR PATIENTS WITH mCRPC RECEIVE THEIR FIRST CHEMOTHERAPY, BE READY FOR WHAT’S NEXT

“ACT” now to get your patients PLUVICTO¹

ACT: 1 ARPI, 1 Chemo, Treat with PLUVICTO for your patients with PSMA+ mCRPC

1 ARPI and 1 taxane-based chemotherapy could have been received at any point in your patient’s prostate cancer journey.^1-3

Prior ARPI

nmCSPC
mCSPC
nmCRPC
mCRPC

Prior taxane-based chemotherapy

mCSPC
mCRPC

See how PLUVICTO helped patients like these in the VISION trial

View OS data

ARPI, androgen receptor pathway inhibitor; mCRPC, metastatic castration-resistant prostate cancer; mCSPC, metastatic castration-sensitive prostate cancer; nmCRPC, nonmetastatic castration-resistant prostate cancer; nmCSPC, nonmetastatic castration-sensitive prostate cancer; OS, overall survival; PSMA+, prostate-specific membrane antigen positive.

PLUVICTO Patient Identification

Dr. Mark Fleming, MD reviews the patient population in the VISION trial and discusses which types of patients may be eligible for PLUVICTO.

Mechanism of Action

LEARN HOW PLUVICTO WORKS

The first and only PSMA-targeted radioligand therapy for men with PSMA+ mCRPC who have been treated with androgen receptor pathway inhibitors and taxane-based chemotherapy¹

Based on in vitro/in vivo studies. Preclinical activity does not correlate with clinical outcomes.

PLUVICTO delivers DNA-breaking radiation directly to PSMA+ metastases

PLUVICTO TARGETS PSMA+ CELLS REGARDLESS OF WHERE THEY HAVE METASTASIZED (BONE, NODAL, OR VISCERAL METASTASES)¹

Lutetium177 (177 Lu) radionuclide and PSMA-targeting ligand

PLUVICTO is comprised of 2 key components: Lutetium-177, a cytotoxic radionuclide, and PSMA-617, a PSMA-targeting ligand.^1,4,5

PSMA biomarker, PLUVICTO, and prostate cancer cell

PLUVICTO binds to PSMA, a transmembrane protein expressed in prostate cancer cells. After binding to PSMA, PLUVICTO undergoes endocytosis and is internalized into the cell.^1,4,6

Cell with radionuclide emitting DNA-breaking radiation

Lutetium-177, the cytotoxic radionuclide of PLUVICTO, emits DNA-breaking radiation within the cell. The short path length of the radiation emitted by PLUVICTO, approximately 2 millimeters maximum, causes single- and double-stranded DNA breaks in the targeted cells as well as surrounding cells, which can lead to cell death.^1,7,8

SCANNING TO CONFIRM PSMA+ mCRPC IS KEY TO IDENTIFYING PATIENTS WHO MAY BENEFIT FROM PLUVICTO.¹

Find information on PSMA-PET/CT scanning for your patients

Learn more about a PSMA-PET scan

CT, computed tomography; DNA, deoxyribonucleic acid; PET, positron emission tomography; PSMA, prostate-specific membrane antigen.

< Previous: About mCRPC & PSMA

Next: Dosing & Administration >

References: 1. Pluvicto. Prescribing information. Novartis Pharmaceuticals Corp. 2. Sartor O, de Bono J, Chi KN, et al; VISION Investigators. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Prostate Cancer V.4.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed May 17, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. 4. Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 1998;58:4055-4060. 5. Ruigrok EAM, van Vliet N, Dalm SU, et al. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020;48(5):1339-1350. doi:10.1007/s00259-020-05057-6 6. Rajasekaran SA, Anilkumar G, Oshima E, et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell. 2003;14(12):4835-4845. doi:10.1091/mbc.e02-11-0731 7. Fendler WP, Stuparu AD, Evans-Axelsson S, et al. Establishing 177 Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer. J Nucl Med. 2017;58(11):1786-1792. doi:10.2967/jnumed.117.193359 8. Nonnekens J, van Kranenburg M, Beerens CEMT, et al. Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib. Theranostics. 2016;6(11):1821-1832. doi:10.7150/thno.15311

Discover PLUVICTO

Identifying Patients

AFTER YOUR PATIENTS WITH mCRPC RECEIVE THEIR FIRST CHEMOTHERAPY, BE READY FOR WHAT’S NEXT

“ACT” now to get your patients PLUVICTO¹

See how PLUVICTO helped patients like these in the VISION trial

PLUVICTO Patient Identification

Mechanism of Action

LEARN HOW PLUVICTO WORKS

The first and only PSMA-targeted radioligand therapy for men with PSMA+ mCRPC who have been treated with androgen receptor pathway inhibitors and taxane-based chemotherapy¹

PLUVICTO TARGETS PSMA+ CELLS REGARDLESS OF WHERE THEY HAVE METASTASIZED (BONE, NODAL, OR VISCERAL METASTASES)¹

Find information on PSMA-PET/CT scanning for your patients

Important Safety Information

Indication

Discover PLUVICTO

Identifying Patients

AFTER YOUR PATIENTS WITH mCRPC RECEIVE THEIR FIRST CHEMOTHERAPY, BE READY FOR WHAT’S NEXT

“ACT” now to get your patients PLUVICTO1

See how PLUVICTO helped patients like these in the VISION trial

PLUVICTO Patient Identification

Mechanism of Action

LEARN HOW PLUVICTO WORKS

The first and only PSMA-targeted radioligand therapy for men with PSMA+ mCRPC who have been treated with androgen receptor pathway inhibitors and taxane-based chemotherapy1

PLUVICTO TARGETS PSMA+ CELLS REGARDLESS OF WHERE THEY HAVE METASTASIZED (BONE, NODAL, OR VISCERAL METASTASES)1

Find information on PSMA-PET/CT scanning for your patients

“ACT” now to get your patients PLUVICTO¹

The first and only PSMA-targeted radioligand therapy for men with PSMA+ mCRPC who have been treated with androgen receptor pathway inhibitors and taxane-based chemotherapy¹

PLUVICTO TARGETS PSMA+ CELLS REGARDLESS OF WHERE THEY HAVE METASTASIZED (BONE, NODAL, OR VISCERAL METASTASES)¹